Announcements
- Wave Life Sciences Announces Positive Results from Phase 1b/2a SELECT-HD Trial with First Clinical Demonstration of Allele-Selective Mutant Huntingtin Lowering in Huntington’s Disease
- Wave Life Sciences Announces Upcoming Presentations Highlighting Novel siRNA Program in Obesity and Leadership in RNA Editing
- Wave Life Sciences to Present at 2024 Jefferies Global Healthcare Conference
- Wave Life Sciences Reports First Quarter 2024 Financial Results and Provides Business Update
- Wave Life Sciences Announces Appointment of Dr. Erik Ingelsson as Chief Scientific Officer
- Wave Life Sciences to Present at 2024 RBC Capital Markets Global Healthcare Conference
- Wave Life Sciences First Quarter 2024 Financial Results Scheduled for May 9, 2024
- Wave Life Sciences Announces Approval of First Clinical Trial Application for RestorAATion-2 Trial of WVE-006 in Individuals with Alpha-1 Antitrypsin Deficiency (AATD)
- Wave Life Sciences Announces Continued Momentum in GSK Collaboration and Advancements in siRNA and RNA Editing
- Wave Life Sciences to Present at Upcoming Investor Conferences
More ▼
Key statistics
On Friday, WAVE Life Sciences Ltd (1U5:DUS) closed at 4.84, 50.31% above the 52 week low of 3.22 set on Jul 05, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 4.82 |
---|---|
High | 4.86 |
Low | 4.80 |
Bid | 4.98 |
Offer | 5.15 |
Previous close | 4.82 |
Average volume | 6.70 |
---|---|
Shares outstanding | 122.48m |
Free float | 102.24m |
P/E (TTM) | -- |
Market cap | 669.94m USD |
EPS (TTM) | -0.5152 USD |
Data delayed at least 15 minutes, as of Jul 05 2024 18:30 BST.
More ▼